Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics (NASDAQ: RNAC) granted employment inducement stock options to four new employees for an aggregate 115,250 common shares, with grant dates of August 3 and August 6, 2026.
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC) granted employment inducement stock options to four new employees for an aggregate 115,250 common shares, with grant dates of August 3 and August 6, 2026. The exercise price for each option equals the Nasdaq Global Market closing price on the respective grant date.
According to Cartesian Therapeutics, the options vest over four years, with 25% vesting on the first anniversary of each grant date and the remaining 75% vesting in substantially equal monthly installments until August 2030. The options have a 10-year term, were issued under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, and approved under Nasdaq Rule 5635(c)(4) as a material employment inducement.
Positive
- None.
Negative
- None.
News Explained
Cartesian has granted options to purchase
Details
News Market Reaction – RNAC
In the Aug 7 session, RNAC gained 1.03%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Employees receiving grants
- 4 employees
- New hires
- Shares underlying options
- 115,250 shares
- Aggregate employment inducement awards
- Effective grant dates
- August 3, 2026 and August 6, 2026
- Option grants
- Vesting period
- Four years
- Option vesting schedule
- Initial vesting
- 25%
- On the first anniversary of each grant date
- Remaining vesting
- 75%
- Substantially equal monthly installments thereafter
- Full vesting date
- August 2030
- Options fully vested
- Option term
- Ten years
- Option term
Historical Context
-
Reported quarterly results, clinical progress, and extended liquidity outlook into 2028.
-
Granted options covering 238,700 shares to eight newly hired employees.
-
Granted one new employee an option covering 6,100 common shares.
-
Partnered with WestGene to develop in vivo mRNA CAR-T therapies.
-
Secured a credit facility providing up to $150 million in financing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year period with
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.